All In Biotech

Drug Trial Radar · NCT04187898

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients With Breast-Cancer Receiving Docetaxel and Cyclophosphamide

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Mar 11, 2020

Primary completion

Jul 16, 2024

Study completion Aug 16, 2024

Sponsor

Lead sponsor
Spectrum Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Dec 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when administered at varying intervals following Docetaxel and Cyclophosphamide administration.

Conditions

  • Neutropenia
  • Breast Cancer

Interventions

  • EflapegrastimBiological

    Administered in Cycle 1, 30 minutes after TC chemotherapy. Administered in Cycles 2-4, on day 2 of each cycle.

  • EflapegrastimBiological

    Administered in Cycle 1, 3 hours after TC chemotherapy. Administered in Cycles 2-4, on day 2 of each cycle.

  • EflapegrastimBiological

    Administered in Cycle 1, 5 hours after TC chemotherapy. Administered in Cycles 2-4, on day 2 of each cycle.

  • EflapegrastimBiological

    Administered in Cycles 1-4, 30 mins after TC chemotherapy.

  • DocetaxelDrug

    75 mg/m\^2 IV infusion. Administered on Day 1 of each cycle.

  • CyclophosphamideDrug

    600 mg/m\^2 IV infusion. Administered on Day 1 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Recovery of Absolute Neutrophil Count (ANC) From Nadir to ≥1.5×10^9/L in Cycle 1Time frame: Cycle 1 is 21 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • ACRC/ Arizona Clinical Research Center

    Tucson, Arizona

  • Yuma Regional Medical Center Cancer Center

    Yuma, Arizona

  • Pacific Cancer Medical Center

    Anaheim, California

  • City of Hope

    Long Beach, California

  • BRCR Medical Center, Inc.

    Plantation, Florida

  • Bond & Steele Clinic, P.A.

    Winter Haven, Florida

  • SCL Health Research Institute, Inc.

    Billings, Montana

  • Mercy Health Youngstown

    Youngstown, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.